X4 Pharmaceuticals, Inc.
XFOR
Positions held
Your positionsXFOR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $276.62M | Enterprise value | $145.87M | Trailing P/E | 139.50 | Forward P/E | -3.64 |
| PEG | — | Price / book | 1.73 | Beta | 0.46 | Dividend yield | 0.00% |
| Revenue growth | 3.5% | Earnings growth | — | Gross margin | 81.5% | Operating margin | -1.9% |
| Profit margin | 0.0% | ROE | -113.1% | ROA | -28.1% | Debt / equity | 0.50 |
| Current ratio | 11.30 | Free cash flow | -$53.31M | Analyst recommendation | none | Mean target | $11.60 |
| 52w high | $4.83 | 52w low | $2.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $2.7M | $2.6M | $1.8M | $2.0M | — |
| Op margin | -186.1% | -749.9% | -922.9% | -1558.6% | -1329.5% | — |
| Net income | -$16.2M | -$20.2M | -$23.9M | -$29.8M | -$25.7M | — |
| Gross margin | 81.6% | 77.9% | 85.8% | 80.1% | 83.5% | — |
| Gross profit | $7.2M | $2.1M | $2.2M | $1.4M | $1.6M | — |
| Operating income | -$16.4M | -$20.3M | -$23.7M | -$27.5M | -$26.2M | — |
- Revenue +225% vs prior quarter ($8.8M vs $2.7M).
- Gross margin 81.6% (was 77.9% prior quarter).
- Operating margin expanded to -186.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0.0M | $0.0M | — |
| Op margin | -247.4% | -5530.0% | — | — | — |
| Net income | -$79.2M | -$37.5M | -$101M | -$93.9M | — |
| Gross margin | 83.6% | 68.8% | — | — | — |
| Gross profit | $29.4M | $1.8M | $0.0M | $0.0M | — |
| Operating income | -$86.9M | -$141M | -$108M | -$88.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
2026-10-08 · X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
2026-10-08 · X4 Pharmaceuticals Enters Up to $150 Million Term Loan Facility
2026-10-08 · X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
2026-10-01 · X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-24 · Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
2026-09-11 · X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-09-09 · X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
2026-09-08 · X4 Pharmaceuticals Reaches FDA Agreement on Revised Phase 3 Trial for Chronic Neutropenia Treatment
2026-09-08 · X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
2026-08-11 · X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
2026-08-06 · X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns